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Abstract
Medication nonadherence can have serious consequences for patient outcomes. Homeautomated telemanagement systems have supported increased levels of adherence among
patients. This project explored whether the use of a home telemanagement program
(HTM) would improve medication adherence in clinic patients diagnosed with
hypertension (HTN). The health belief model, social learning theory, the self-regulation
model and the theory of reasoned action guided this project. Providers in a primary care
clinic completed the 4-question Morisky, Green, and Levine adherence scale with 50
HTN patients previously enrolled in a HTM. Survey results revealed that after 2 years in
the program, patients were still forgetting to take their medications (56%), stopped taking
their medications when they felt better (54%), stopped taking their medications when
they felt worse (66%), or were careless at times about taking medications (38%). Data
collection did not take place prior to beginning the HTM program; therefore, pre- and
post-data for medication adherence behaviors were not compared. Project data support
the importance of medication adherence and the consequences of nonadherence for all
patients taking HTN medications. Monitoring of these patients is recommended to
continue exploring if participation in HTM programs can support positive social change
by improving health outcomes for HTN patients.
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Section 1: Nature of the Project
Introduction
Approximately 75 million individuals in the United States are presented with the clinical
condition of hypertension (HTN) (Centers for Disease Control [CDC], 2017). Out of the
estimated number of HTN patients, 46% of individuals revealed uncontrolled blood pressure
(BP) (CDC, 2017). Considering the complications of HTN the reported rate of mortality is 9.5
per 100,000 every year (CDC, 2017). Additionally, uncontrolled HTN is underpinned with the
increased risk of myocardial infarction, stroke, heart disease, renal disease and mortality (CDC,
2017). Several researchers have noted that the incidence of uncontrolled HTN in the United
States has resulted from regional differences and other factors (Joffres et al. 2013; Yoon et al.
2014; Sampson et al. 2014). Medication adherence is a critical part of disease management. The
World Health Organization (WHO) reported that by 2020 50%-60% of patients will be nonadherent to medications, and experience increased mortality and morbidity (Lam & Fresco,
2015).
The integration of home-assisted tele management (HTM) provides significant assistance
in managing blood pressure of patients at home, alongside promoting effective partnership
between care providers and family members of the patients (Lee & Park, 2016). The care
facilitated through the use of the technology encompasses a patient-centered approach, which in
turn, is associated with improved satisfaction of the patients and provision of care by innovative
means (Zullig, Melnyk, Goldstein, Shaw, & Bosworth, 2013). The use of HTM helps in the
attainment of better prognosis related to cardiovascular mortality as compared to monitoring
performed in a clinic (Kitsiou, Pare, & Jaana, 2015). The use of such technology during care
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provision assists care providers in the effective management of hypertension in the form of
updated patient data (Lee & Park, 2016).
Problem Statement
The nursing practice problem for this project was medication adherence. Medication
nonadherence is a factor that contributes to increased mortality rate, especially in patients with
cardiovascular diseases, such as hypertension Medication nonadherence can also cause
unnecessary healthcare expenditures and increased hospital readmissions (Yoon et al. 2014; Lam
& Fresco, 2015; Solomon et al. 2015). In an effort to increase medication adherence with
patients diagnosed with HTN, the primary care clinic instituted a HTM program. The clinic was
seeking to evaluate medication adherence comparing those patients using HTM and those
patients not enrolled in HTM.
Purpose Statement
The purpose of this project was to evaluate the improvement in medication adherence in
hypertensive patients through the use of HTM. The practice question was: Will the use of HTM
improve medication adherence in clinic patients diagnosed with HTN? HTM has been shown to
improve medication adherence (Lam & Fresco, 2015). This project had the potential to
contribute to social change by improving the lives of patients with HTN through HTM support,
in addition; the project may contribute to decreased hospital admissions and improve quality of
life for these patients and their families. This project followed the Walden University DNP
Manual for Evaluating Quality Improvement Projects.
Nature of the Doctoral Project
This quality improvement evaluation project was conducted in a primary care clinic in an
urban city in the southeast United States (US). The clinic instituted HTM two years ago in an

3
attempt to improve medication adherence with their hypertensive patients. No evaluation of the
program had been completed. Providers in the clinic completed a medication adherence
questionnaire (MGL)(Morisky, Green & Levine, 1986) for patients diagnosed with HTN over a
three-month period. Participants included patients using HTM and those who are not. Descriptive
statistics were used to describe the medication adherence profile of both groups.
The 4-point scale is the most widely used scale for medication adherence measurement.
This scale was initially published in 1986. Since that time, it has been used to assess medication
adherence for a wide range of diseases and in many languages (Morisky, Green, & Levine,
1986). Online databases from the Walden library were explored. Peer-reviewed literature over
the past five years (2013-2018) was reviewed using key words such as medication adherence,
medication non-adherence, medication compliance, medication noncompliance, telemedicine,
home tele-monitoring, telemedicine and hypertension.
Significance
The physiological effects of HTN have been shown to contribute to the development of
life-threatening conditions of stroke, coronary artery disease, and renal failure. (AHA, 2014;
CDC, 2017). These complications from HTN have care costs as high as $51 billion dollars
annually (Wang, Grosse, & Schooley, 2017; Mozzafarian, Benjamin & go, 2015). Almost onehalf of the entire expenditure was related to prescribed medications. Enormous efforts have been
invested in public health with the aim of reaching the goal designed by the Healthy People 2020
for the improvement of elevated BP (Martin et al. 2013). This project explored the use of home
tele-monitoring as a means to improve patient adherence to medication regimes. The
stakeholders for the project were health care provider and patients with HTN.
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Summary
Section 1 introduced the problem of medication adherence in patients in a clinic setting.
This project was an evaluation of the clinic’s quality improvement initiative to implement HTM
with HTN patients. The practice question was: Will the use of HTM improve medication
adherence in clinic patients diagnosed with HTN? The MGL was administered to clinic patients
with a diagnosis of hypertensive. Section 2 introduced the model supporting this project and the
evidence related to HTM.
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Section 2: Background and Context
Introduction
The purpose of this DNP project was to evaluate the quality improvement project related
to HTM as a means to improve medication adherence in hypertensive patients by targeting a
local mid-city clinic in an urban city United States. The practice question was: Will the use of
HTM improve medication adherence in hypertensive clinic patients? Clinic providers
administered the MGL questionnaire to patients with HTN during one clinic visit over a threemonth period. Data was compared between patients receiving HTM and those who do not
participate in HTM.
Concepts, Models, and Theories
The Medication Adherence Model (MAM) was developed by Johnson (2002) after a
qualitative content analysis comparing factors associated with adherence and nonadherence to
HTN medications. The model was built on the underlying principles of several well research
models: Health Belief Model, Social learning Theory, the Self-Regulation Model and the Theory
of Reasoned Action. Three core concepts framed the model: (a) purposeful action, (b) patterned
behavior, and (c) feedback. The assumptions of this model include the following:
•

Individuals want to maintain their health

•

Individuals value health

•

HTN is detrimental to one’s health and well-being

•

Effective treatment of HTN includes medication

•

Prescribed medications for HTN are in the best interest of persons with HTN
(Johnson, 2002).
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Table 1 describes the three core concepts and their relationships to each other and to medication
adherence, which is adapted from Johnson (2002).
Table 1: Medication Adherence Model

Purposeful Action

Purposeful action denotes a deliberate
decision influenced by the perceived need and
perceived effectiveness of the medication.
This is an intentional decision associated with
the cognitive process of decision making.
The decision is made to take the medication,
one develops a patterned behavior which is
dependent on access, routine, and
remembering.
Both purposeful action and patterned behavior
are being constantly evaluated via feedback
through facts, prompts and events.
Adherence will be maintained or modified
based on continuous feedback.

Patterned Behavior

Feedback

Adherence

Definitions of Terms
Compliance: Compliance is related to the degree to which a patient follows a medical advice
(Vrijens et al. 2017).
Adherence: Adherence can be explained as the extent to which an individual follows the
recommendations highlighted by a healthcare professional (Vrijens et al. 2017).
HTM: A telecommunication technology used for the distribution of any health care service
among patients (Lam & Fresco, 2015).
Relevance to Nursing Practice
Medication Nonadherence
The main difference between compliance and adherence is that the adherence requires
consent of the patient with the recommendations received. Adherence also expresses an active
collaboration between health professional and patient in making decisions that affect healthcare
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outcomes. On the contrary, the term compliance implies a behavior of submission and obedience
to an order, typical of a paternalistic relationship between health professionals and the patient
(Nielsen, Shrestha, Neupane, & Kallestrup, 2017). This lack of patient participation in the
definition could justify the disuse of the term compliance in favor of adherence, but in practice
both terms continue to be used interchangeably. Adherence is defined as the total number of days
of medication taking according to the prescriber's guidelines during the follow-up period.
Persistence is defined as the number of days of continuous use of the medication during a
specific period (Vrijens, Antoniou, Burnier, de la Sierra, & Volpe, 2017). It can be established
for each individual a period of grace or allowed interval to obtain or recharge the prescribed
medication (in this case, 10 days). If the patient exceeds this predetermined interval, it is
considered not to be persistent. The adherence and persistence rates are calculated by dividing
the number of days the patient has been adherent or persistent, respectively, by the number of
days of the follow-up period (in this case, 360 days) (Hamdidouche et al. 2017).
Recently, the International Society of Pharmacoeconomics and Health Outcomes
Research (ISPOR) has defined therapeutic adherence, as a degree to which a patient act in
accordance with the dose by considering a prescribed dosage within a suggested period.
However, the clinical results of a treatment are affected not only by how patients take their
medication, but by how long they do it (Calderon-Larranaga et al. 2016). For this reason, the
term persistence has been used in recent years to define the time during which the patient
continues with the treatment, that is, the amount of time that elapses from the beginning to the
interruption.

8
Medication Nonadherence in HTN
Nonadherence to medications is now considered as a major health issue at the public
level. Patients tend to project nonadherence when provided with a new prescription of medicines,
including the patients presented with HTN (28.4%), diabetes (31.4%), and hyperlipidemia
(28.2%). In context to the high rate of medication nonadherence, the percentage of morbidity and
mortality among the patients with chronic clinical conditions has increased. In addition to this,
poor or nonadherence to medication provided for the management of heart disease increases the
number of emergency visits in the cardiovascular department and making nurses care demand
rise and more stress to nursing practice with increase in shortage of the providers as well as the
health care cost (Tomaszewski et al. 2014).
Factors Leading to Nonadherence
There are several factors that can lead to an adherence problem, many of them closely
related. Age, cultural and social environment of the patient, the level of education, as well as
their personality, condition is responsible for affecting treatment outcome (Adler et al. 2017).
Some patients do not comply with the treatment because of the belief that they have not been
treated correctly or that the medication is not effective, or because they have difficulty
understanding the medical explanations related to the treatment. Other times the cause is a
simple forgetfulness or difficulties when getting medication (Bazargan et al. 2017). Finally, it is
necessary to highlight the special relevance of this problem in two special populations including
elderly and children, in which aspects such as safety or simplification of therapeutic regimens are
key aspects.
Adverse effects are regarded as the interruption of treatment due to the appearance of
adverse effects is one of the most common causes of non-adherence. These can be the cause of
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the abandonment of the therapeutic guideline or they can also appear as a consequence of the
lack of follow-up of the medical recommendations on the dosage guidelines (Mongkhon,
Ashcroft, Scholfield, & Kongkaew, 2018). Characteristics of the active ingredient:
pharmacodynamics, pharmacokinetics, and pharmaceutical form and characteristics. Frequently,
the patient projects non-adherence to treatment if he does not observe a beneficial result derived
from its short-term use. An important factor that leads to non-adherence is the complexity of the
patient’s therapeutic regimen, which also produces an increase in the probability of error in
taking the medication. Therefore, the simplification of the treatment increases the adherence of
the patient to the therapy and in this way the probability of positive results (Mongkhon, Ashcroft,
Scholfield, & Kongkaew, 2018). Cost is related to the increase in the price of drugs, as well as
the increase in the co-payment of publicly financed medicines, causes an increase in the cost of
medicines for the patient. Therefore, may constitute a barrier to adherence with the therapeutic
regimen.
Of all the factors mentioned above, some of them have been identified as key predictors
of low adherence to medication. These are: lack of knowledge of the disease, the therapeutic
regimen and the consequences of non-adherence on the part of the patient, lack of an adequate
relationship between the patient and complexity (Calderon-Larranaga et al. 2016). Long duration
of treatment, asymptomatic disease, inadequate follow-up or lack of an elaborate plan on the
abandonment of medication; presence of adverse effects, cost of medication and / or copayment,
not attending medical appointments, presence of psychological problems such as depression or
anxiety, beliefs and perceptions of the patient about medication and presence of cognitive
difficulties are other major factors (Calderon-Larranaga et al. 2016).
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Nielsen et al. (2017) stated that poor adherence to long-term treatment severely
compromises the effectiveness of treatments, especially in those who have a greater probability
of leading a non-compliant behavior over time. Therefore, this study is based on the need to have
sensitive and applicable instruments in different situations quickly and economically, which
allow to adequately measure this behavior, and thus manage differentiated, precise and focused
interventions, reducing premature morbidity and mortality in this group of people (Foot et al.
2016). In this sense, Morisky's medication adherence scale has been frequently used in research
on adherence to antihypertensive treatment.
Clinical Consequences
Clinical consequences are derived from the increase in mortality or morbidity observed in
non-compliant patients. The importance and time horizon in which these consequences will
develop will depend fundamentally on the type of drug prescribed and the disease for which its
use is intended (Nafradi, Galimberti, Nakamoto, & Schulz, 2016). There is a clear and direct
association between the lack of compliance and obtaining worse results in health. The difference
between effectiveness and effectiveness of the treatments is even more evident in the presence of
HTM (Pandey et al. 2015). The achievement of acceptable levels of compliance helps to know
the real benefits of drugs and avoids the appearance of uncertainty about their effectiveness.
Considering the importance of knowing the prevalence of problems of adherence to
treatment and its determinants for the design of effective intervention strategies, it is expected
that the prevalence of having problems of adherence to the treatment (at least presenting a
problem of adherence) is significant (Burnier, 2017). Older people with higher education, who
evaluate their illness as more serious and longer, perceive more benefit and control of the disease
through treatment, understand their illness better, report more support from the family, and take
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less years treating each other have fewer adherence problems to the medication. Patients with
chronic diseases comply with 50% to 60% of the indicated pharmacological treatments. In the
US, it is estimated that 125,000 deaths per year occur due to non-compliance and that between
33% and 69% of hospital admissions related to medication are due to non-compliance with
treatments (Schoenthaler, Knafl, Fiscella, & Ogedegbe, 2017). It is also estimated that half of the
50% reduction observed in the last 20 years in mortality from ischemic heart disease is due to
cardiovascular drugs. However, the achievements of these benefits are lost due to the high
default rates in real situations.
The inability to identify and remedy non-compliance commonly results in
pharmacological therapies with higher doses of medications. This brings increases in the cost of
the treatments, in the risk of adverse events, in the wrong diagnoses and, in extreme cases, in
unnecessary treatments, aggravation of the disease and mortality (Omboni & Ferrari, 2015
Hedegaard et al. 2015). The WHO report also stated that the magnitude of the breach and its
consequences are so alarming that improving compliance with existing treatments would bring
greater global benefits than the development of new medical treatments. It is very likely that the
transfer of interventions to large-scale real situations will be unsuccessful, in particular due to the
lack of personnel to supervise the administration of the intervention and the monitoring used in
clinical trials (Lo, Chau, Woo, Thompson, & Choi, (2016)). Some simple strategies that result in
a small effect at the individual level can result in a substantial benefit in public health. A
retrospective analysis of more than 3,000,000 individuals found this type of results when a
blister-type package with a calendar for a daily cardiovascular drug was used (Yap,
Thirumoorthy, & Kwan, 2016).
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Role of Healthcare Professionals and Patients’ Behavior
The second problem is that interventions focus on the doctor. Healthcare professionals
have limited or no control over the drug taking behaviors. Interventions that facilitate open
communication are more likely to endure. It would seem that patients’ perspectives are not taken
into account, data on the relationship between patients and physicians are omitted and
approaches that take shared decision-making are lacking (van Boven et al. 2016). Interventions
strive to achieve an objective (based on research) that may not be consistent with the role that
medications play in the context of the patient's daily life. Interventions are needed that increase
patient participation, improve the skills and behaviors of taking the different drugs and improve
self-assessment and corrections, both in patients and doctors, regarding the use of medications.
A personalized and multi-faceted strategy is more effective. This is of great importance,
since more than 100 factors associated with non-compliance have been observed. Effective
interventions address barriers those related to literacy on health, those of necessary behavioral
changes and administrative barriers related to access, and fragmentation of the health system.
Interventions for patients with low literacy in health include educational materials with images,
easy to understand, explanations in layman's terms, audiovisual presentations, the generation of
environments for patients and practitioners to pour their questions and doubts and training on
communication forms to all responsible people involved in the health system (van Boven et al.
2016). The inclusion of a spouse or family member increases effectiveness. Requesting
demonstrations and repetitions of the information to the patient or companion assures that this
was heard and understood.
Patients need behavioral skills that allow them to adopt and integrate taking medications
into their daily lives. Among the strategies to improve compliance are self-assessment (the use of
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diaries, records, packaging with calendars, electronic reminders, alerts), positive reinforcement
(incentives, rewards) and forming associations to share responsibility (contracts between doctor
and patient, internet support groups) (Vrijens et al. 2017). Compliance with pharmacological
treatment is a responsibility and an objective shared by all the members of the health group
(patient, family, doctors, and members of the different institutions). This objective is agreed
according to the priorities and the purposes of the selection of the medicines and according to the
administration and the behaviors of the taking of the medicines. Communication and flow of
information between patients, physicians and institutions is needed to improve compliance
(Hamdidouche et al. 2017). Opportunities to bridge the gap in communication take place in every
instance of the process.
Healthcare professionals can succeed with participation at the local level, beyond the
changes to be made at higher and national levels. Both patients and doctors can benefit from the
analysis of performance with respect to the objectives set. It should be borne in mind that the
time of the evaluation may result in predictable maximum and minimum points. Compliance is
greater in five days before and five days after a visit to the doctor, while it decreases after 30
days (Nafradi et al. 2016). Therefore, improving compliance in the treatment of chronic diseases
depends on the moments chosen for the evaluation, the open and continuous communication and
the sensitivity to predict these patterns of maximum and minimum. Ideally, intervention
programs can predict who will present compliance problems and when. Algorithms have been
developed for this purpose (Pandey et al. 2015). The pharmacist also plays an important role in
ensuring that pharmacological therapy is appropriate and that there is communication about the
changes in it between the main actors (patient and doctor).
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Conn et al. (2015) measured pharmacological adherence, leaving aside other aspects such
as diet, exercise, activity physical and general lifestyle changes that are part of the therapeutic
regimen and allow evaluation of adherence in an integral way. When referring to adherence, it is
common to use the term compliance of the patient. This care provider approach can reduce the
role of patient to a more passive or subordinate role. In this perspective, patients are not given
the opportunity to participate in the decision-making process with regard to the adoption of their
own regime for therapeutic a lifestyle change. As the measurement of the adherence moves to an
approach in which patients assume a more active and dynamic role to negotiate the adoption of
an established therapeutic regimen, the patient takes into account their beliefs and sociocultural
context. The dynamic model of adherence suggests that knowledge about how the patient makes
decisions related to his medication and the interaction between the person-team of health, plays a
vitally important role in understanding the new therapeutic regimen which the patient will adopt.
Schuiling-Veninga et al. (2017) recognized that the dynamic concept of adherence has an
implicit role in active collaboration and voluntary participation of the patient in the adoption of a
healthy lifestyle. These changes favor changes in diet, exercise, and intake of medication
prescribed by health personnel. Under this view, the therapeutic regimen of each person is
voluntary in nature and plays an active role in the beliefs and context in which the patient is
immersed (Thom et al. 2015). It becomes necessary to choose a method to measure the
adherence concept in a comprehensive approach especially in people with long-term therapeutic
regimens.
Morisky Scale
Beginning in 1986, Dr. Morisky and colleagues developed a four-item medication
adherence scale. The scale was modified in 1008 to include eight items with a Cronbach alpha of
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.83. Currently, the eight-point scale is not available for individual use. However, the revised 4point scale, the Morisky, Green & Levine Scale, or MGL, is available in the public domain and
had been cited over 4500 times in peer-reviewed journals since its publication in 1986 (Morisky,
et al., 1986).
The MGL consists of four questions and requires a yes or no response.
1. Do you ever forget to take your medicine?
2. Are you careless at times about taking your medication?
3. When you feel better, do you sometimes stop taking your medication?
4. Sometimes, if you feel worse when you take the medicine, do you stop taking it?
(Morisky, Green, & Levine, 1986).
Home Assisted Telemanagement (HTM)
HTM is the distribution of any health care service using telecommunications
technologies. HTM can be defined as the use of information medical exchanged from one place
to another through the use of technology from information and communications (ICT) to
improve the patient’s health status (Conroy, Zhan, Culpepper, Royal III, & Wallin, 2018). HTM
is a promising methodology for providing services to patients presented with chronic conditions
who are readily prone to encounter barriers related to accessing attention or a heavy burden of
the disease.
HTM is effective specifically in heart failure and diabetic disease monitoring, as remote
monitoring and telephone support for problems in which cardiovascular diseases have shown a
reduction of hospitalization in emergency room visits, delays in hospitalization, admission to
hospital, duration of hospital stays, and mortality from these causes. An improvement in the
quality of life and a reduction of costs have also been reported among the patients presented with
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the condition of uncontrolled HTN (Jeong & Finkelstein, 2015). Communication through HTM
also can increase formal prevention for those who do not have access to cardiac rehabilitation.
According to Jeong and Finkelstein (2016), investigations carried out through HTM indicated
benefits to patients with heart disease, as they constitute the cause of hospitalization more
frequent. On the other hand, less favorable results have been found in respiratory pathologies.
Remote monitoring for respiratory problems has shown a better control of symptoms and one
more early identification of deterioration. The receptivity and positive attitude of patients is
promising, but the evidence about the clinical and structural effects are only preliminary. For
chronic problems in older people the most effective interventions provided through HTM are
automatic monitoring of vital signs, which reduces the use of health services and telephone
follow-up by nursing staff who improves clinical indicators, alongside reducing the use of health
services.
Finkelstein, Cisse, and Jeong (2015) stated that HTM is effectively integrated in the areas
such as alcohol abuse, problems of overweight and mental disorders. For mental health problems
psychotherapy by HTM is as significant as face-to-face approach. However, for the success of
telepsychiatry it is necessary to take into account human aspects and of organization in addition
to legal aspects and ethical aspects. Gross-Schulman, Sklaroff, Hertz, and Guterman (2017)
addressed that the care remote services provided through HTM are profitable in reducing the use
of hospitals, improve organization of care, evaluation of attention procedures, trust of patients
and their satisfaction, and quality of life. Nevertheless, Briscoe and Quezada (2016) depicted that
the available studies are scarce and heterogeneous, as the studies focuses on socio-political
environments and organizations of limited comparability.
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According to Fang, Maeder, and Bjering (2016), the integration and the level of
resolution of the HTM resulted that initial care can be guided and elaborated by a health
professional with diagnostic capacity who has all the powers to establish a protocol of
cardiovascular rehabilitation using the tool of HTM for internal medicine, cardiology,
endocrinology, nutrition, and diet. It should be noted that a fundamental part of the management
of this type of pathology goes hand in hand with training and the incorporation of healthcare
professionals who are in the care and control of the patient (Mariotte & Starr, 2018). This
constitutes a valid strategy that generates a control of non-communicable chronic disease of
patient, reducing the entrance to the services of emergencies due to acute cardiovascular
disorders. Another part is related to the contribution to the welfare of the adult, improving their
quality of life, and providing more useful service time to society.
Effectiveness of HTM
The system for HTM technology is developed by including a unit for patient, a server for
supporting decision, and a web-based portal for healthcare professionals. The patient unit is
connected to a laptop computer along with an electronic weight scale. A serial port is used for
connecting the scale with the laptop. A software is used through the laptop and the interface
displays a keyboard that can be used for operating only three keys (Briscoe & Quezada, 2016).
The process of self-testing is required to be completed by the patients on weekly basis for the
duration of six months. In addition to this, data collection is carried out by considering use of
medications, symptoms, and adverse effects in a diary. The self-testing results are then
automatically transferred to the server of the HTM which leads to the generation of computerized
alert to inform the healthcare provider in case of clinical condition detection (Briscoe &
Quezada, 2016).In the evaluation of the HTM project, Yanicelli et al. (2015) have identified a
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number of benefits that show a positive health impact on the population of its area of influence,
but some benefits have not been valued so far, such as savings in costs for the services provided
to these patients and transfers of control by medicine specialized. The reduction of adult
pathologies points to improve the objectives of reducing the mortality of public health plans for
the millennium through an impact and benefit strategy towards this type of population, which at
the same time is decisive and low cost for hospitals (Purcell, McInnes, & Halcomb, 2014). On
the other hand, HTM also seeks to bring technological resources in favor of the patient’s
assessment of the border area in the country, alongside delivering tools for the development of
medical activities that contribute to the control and good functioning of prevention programs for
the promotion of hospital extensively.
The evaluation of the economic consequences of HTM is hindered by methodological
problems, such as the difficulty of establishing a consensus on its definition and assessment, and
the design of the study that assesses the economic impact, the identification, measurement and
assessment of costs and results (Kim, Wineinger, & Steinhubl, 2016). In addition, it also entails
the problem in the interpretation of this value in controlled studies. The deficiency in the
fulfillment of the outlined health objectives has an impact in the vast majority of situations on an
increase in costs. These are generated due to the increase in hospitalizations and visits to
ambulatory and emergency centers, which increases or changes in prescription or performance of
more invasive diagnostic tests. In the US, it has been estimated a cost of 100 billion dollars a
year derived from the incorrect taking of medication. Of this cost, 25 trillion corresponded to
hospital admissions and 70 trillion, to loss of productivity and premature death as a result of
cardiovascular diseases (Schuiling-Veninga et al. 2017). Costs increase as a result of the high
levels of mortality and morbidity. For example, in the case of HTN, in which HTM contributes
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to the effectiveness of treatments and causes a direct effect on costs and rehospitalizations. These
are the main costs associated with the disease, so that therapeutic compliance in HTN is the key
to controlling their derived costs (Thom et al. 2015).
Observational studies have shown that reducing co-payments for high-efficacy chronic
therapies can substantially improve compliance. In addition, when doctors indicate generic or
lower-cost medications, compliance improves (Krousel-Wood et al. 2015). Others have proposed
that the reduction of co-payments may not be sufficient, but that monetary rewards for good
compliance seem to be a more effective mechanism for behavioral change. A significant impact
has been demonstrated with monetary incentives to quit smoking and lose weight. Therefore, the
use of HTM can improve the connectivity of patients, doctors, pharmacists and the health
system. It is currently used to generate measurements on the quality of drug administration and
monitoring (Lam & Fresco, 2015). When information about medications is shared electronically,
those who indicate them have access to information that allows them to evaluate the regimen and
identify noncompliance with treatment.
Local Background and Context
Hypertension is an increase in human blood pressure in the arteries, which is a major risk
factor for heart disease and stroke. Locally, it is measured in two criteria, systolic (contracting
heart muscle) and diastolic (relaxing the heart muscle). HTN is classified as one of the clinical
conditions that underpin a pronounced risk of developing cardiovascular diseases. Considering
the manifestation of the condition in the United States, it is responsible for contributing to high
rate of morbidity and mortality in the population in the form of a primary cause and fourth
leading reason of death (CDC, 2017). Tomaszewski et al. (2014) highlighted that nonadherence
to medications is now considered as a major health issue at the public level. Furthermore,
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patients tend to project nonadherence when provided with a new prescription of medicines,
including the patients presented with HTN (28.4%), diabetes (31.4%), and hyperlipidemia
(28.2%). In context to the high rate of medication nonadherence, the percentage of morbidity and
mortality among the patients with chronic clinical conditions has increased. Poor or
nonadherence to medication to manage heart disease increases the number of emergency visits in
the cardiovascular department and making nurses care demand rise and more stress to nursing
practice with increase in shortage of the providers as well as the health care cost.
The clinic is located in a large metropolitan area in the southeast U.S. The clinic provides
primary care services to a primarily underserved population. The majority of the patients are
African American and Latino and are insured through Medicare or Medicaid. The providers
report that upon questioning patients about their adherence to the medication regime, many
report that once they feel better, they stop taking their medications. Others appear to just forget
about taking the medications. The clinic implemented the HTM program approximately two
years ago to address the identified problem of patients reporting non-adherence to their
medication regimen. Up to this point no evaluation of the program has been completed. The
clinic is supportive of evaluating the effectiveness of the HTM with medication adherence in
patients with HTN.
Role of the DNP Student and Project Team
The project team consisted of clinic providers who completed the MGL for each patient
diagnosed with HTN. The providers completed one MGL for each patient over a three-month
period. The de-identified forms (Appendix A) were shared with me.
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Summary
The purpose of this project was to evaluate the improvement in medication adherence in
hypertensive patients through the use of HTM. The practice question was: Will the use of HTM
improve medication adherence in clinic patients diagnosed with HTN? Section 2 described the
concepts of the MAM, definition of terms associated with the project, the evidence-based
literature relevant to the project as well as my role and the role of the project team. Section 3
discussed the plans for evaluation of the quality improvement project as well as data analysis and
synthesis.
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Section 3: Collection and Analysis of Evidence
Introduction
The nursing practice problem highlighted in this DNP project was related to medication
adherence, which is a factor commonly attributed to increased mortality among patients suffering
from cardiovascular diseases such as hypertension (Yoon et al. 2014). The purpose of this project
was to evaluate the improvement in medication adherence in hypertensive patients through the
use of HTM. The practice question was: Will the use of HTM improve medication adherence in
clinic patients diagnosed with HTN?
Nonadherence to medications is now considered as a major health issue at the public
level. Due to the high rate of medication nonadherence, the percentage of morbidity and
mortality among the patients with chronic clinical conditions has increased. In addition to this,
poor or nonadherence to medication provided for the management of heart disease increases the
number of emergency visits in the cardiovascular department and making nurses care demand
increase, adds stress to nursing practice and increases the health care cost (Tomaszewski et al.
2014). The local problem is poor adherence to HTN medication, which in turn, leads to the
development of life-threatening conditions, hospital readmissions, and decreased quality of life.
Medication nonadherence is an issue that requires consideration since it has the potential
to affect not only the health outcomes but also the overall healthcare costs. By 2010, healthcare
costs described as wasteful amounted to 30% of America’s health care expenditure (Ebbert,
2012). Medical nonadherence contributes to the waste of medical resources. There is a need to
devise mechanisms to deal with the problem before it causes more damage. Evaluation of the
HTM program as a means of mitigating medication nonadherence may provide additional
evidence into improving medication compliance.
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Practice-focused Question
The purpose of this project was to evaluate the improvement in medication adherence in
hypertensive patients through the use of HTM. The practice question was: Will the use of HTM
improve medication adherence in clinic patients diagnosed with HTN?
Sources of Evidence
Patients with a diagnosis of HTN were requested to respond to the questions on the MGL
(appendix A) by clinic providers during their office visit. The providers completed a MGL
during one patient visit for each patient diagnosed with HTN during a three month period. These
de-identified MGLs were shared with me by the clinic administrator.
This 4-point scale is the most widely used scale for medication adherence measurement.
Permission to use the MGL scale is found in Appendix B. The MGL consists of four questions
and requires a yes or no response (Morisky, Green, & Levine, 1986).
1. Do you ever forget to take your medicine?
2. Are you careless at times about taking your medication?
3. When you feel better, do you sometimes stop taking your medication?
4. Sometimes, if you feel worse when you take the medicine, do you stop taking it?
Analysis and Synthesis
The de-identified responses were entered in Microsoft Excel. Descriptive statistics were
used to compare the responses from patients using HTM and patients not using HTM.
Summary
When medication nonadherence is addressed, treatment for chronic diseases such as HTN
can be more effective. HTM is a cost- effective way to monitor medication adherence. Section 3
described the process of data collection, analysis and synthesis of project results. The purpose of
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this project was to compare responses in the MGL between patients using HTM and those not
using HTM. The practice question was: Will the use of HTM improve medication adherence in
clinic patients diagnosed with HTN? Section 4 described the findings and dissemination of the
evaluation of the quality improvement initiative.
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Section 4: Findings and Recommendations
Introduction
Current evidence posits that the effectiveness of the treatment of HTN depends not only
on the correct and timely diagnosis and the choice of the optimal strategy and tactics of
treatment, but also on patient compliance with the prescribed therapy regimen (Krousel-Wood et
al. 2015). Thus, it has been established that measuring blood pressure is not a reliable method for
assessing compliance with recommendations in hypertensive clinic patients in everyday practice.
Much more accurate information can be obtained with careful questioning of the patient.
(Krousel-Wood et al. 2015). Section 4 described the results of data collected by the facility
using the Morisky questionnaire. The sample size for this project was 80 clinic patients with a
diagnosis of hypertension. The practice question was: Will the use of HTM improve medication
adherence in clinic patients diagnosed with HTN?
Findings and Implications
Evidence for this project was the de-identified surveys completed by the clinic providers
over the past three months. The de-identified surveys were shared with me and data was
analyzed using Microsoft Excel. Eighty patients responded to the survey questions. Out of 80
participants selected in the survey 50 patents were reported to use HTM while 30 patents were
not using HTM. Table 1 describes the total number of participant responses. Although 66% of
patients do not stop taking their medications even if they feel worse, responses to the questions
about forgetting the medications, stopping medications if they feel better, and forgetting to take
medications had more yes responses than no responses.
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Table 1
Total Responses to MGL Survey
Question
Do you ever forget to take
your medicine?
Are you careless at times
about taking your
medication?
When you feel better, do you
sometimes stop taking your
medication?
Sometimes, if you feel worse
when you take the medicine,
do you stop taking it?

Yes Response
47 (59%)

No Response
33 (41%)

44(55%)

36(45%)

37(46%)

43(54%)

53(66%)

27(34%)

Table 2 depicts the responses to the 50 patients participating in the HTM program and the
30 patients not enrolled in the program. For the question do you ever forget to take your
medicine 56% of the HTM patients responded yes but only 37% of the non-HTM participants
responded yes. For the question are you careless at times about taking your medication both
groups had more patients responding no than yes. For the question when you feel better, do you
sometimes stop taking your medication 54% of the HTM patients responded yes but only 13% of
the non-HTM patients responded yes. For the final question sometimes, if you feel worse when
you take the medicine, do you stop taking it 66% of the HTM patients responded yes while 33%
of the non-HTM patients responded yes.
The practice question was: Will the use of HTM improve medication adherence in clinic
patients diagnosed with HTN? The results of the surveys revealed that more than 50% of the
HTM patients still are forgetting to take their medications, stop taking their medications when
they feel better, stop taking their medications when they feel worse. However, over 50% in both
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groups did not feel they were careless about taking their medications. Since there was no data
from the HTN patients prior to beginning the HTM program, there was no comparison data.
Table 2
Responses Participants and Non-Participants in HTM
Question

HTM Patients
Response Yes
28 (56%)

HTM
Patients
Response No
22 (44%)

Non HTM
Patients
Response Yes
11 (37%)

Non HTM
Patients
Response No
19 (63%)

Do you ever forget to take
your medicine?
Are you careless at times
about taking your
medication?
When you feel better, do you
sometimes stop taking your
medication?
Sometimes, if you feel worse
when you take the medicine,
do you stop taking it?

19 (38%)

31 (62%)

5 (17%)

25 (83%)

27 (54%)

23 (46%)

4 (13%)

26 (87%)

33 (66%)

17 (34%)

10 (33%)

20 (67%)

Recommendations
Since over 50% of the participants are still forgetting to take their medications, stop
taking their medications when they feel better, stop taking their medications when they feel
worse, there should be more discussion with patients and providers related to medication
adherence. Providers could ask patients to provide specific examples related to their responses.
Also, an education guide with key points could be developed and provided to patients.
Strengths and Limitations of the Project
The project was a good start in understanding medical adherence in HTN patients.
Although the project question did not include non-HTM patients, the data revealed that more
discussion should occur about the importance of medication adherence and the consequences of
non-adherence with all patients taking hypertensive medications.
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Summary
Section 4 discussed the data results for the projects, and strengths and limitations
of the project. The practice question was: Will the use of HTM improve medication adherence in
clinic patients diagnosed with HTN? The results of the surveys revealed that more than 50% of
the HTM patients still are forgetting to take their medications, stop taking their medications
when they feel better, stop taking their medications when they feel worse. Since there was no
data on the HTM patients prior to beginning the HTM program, there was no comparison data.
However, since over 50% of these patients are still not adhering to medication regimes patients
need further education and monitoring of medication adherence.

29
Section 5: Dissemination Plan
This quality improvement evaluation project was conducted in a primary care clinic in an
urban city in the southeast U.S. The clinic instituted HTM two years ago in an attempt to improve
medication adherence with their hypertensive patients. No evaluation of the program had been
completed. Providers in the clinic completed the MGL questionnaire (Morisky, Green & Levine,
1986) with 50 patients participating in a HTM program. over a three-month period. Results of the
self-reported responses revealed that over 50% of the enrollees were still forgetting to take their
medications, stop taking their medications when they feel better, or stop taking their medications
when they feel worse. These results were shared with clinic providers with the recommendation
that further exploration of why patients are still having difficulty with medication adherence.
Providers should explore additional options to improve medication adherence.
Analysis of Self
The concept of telemedicine is here to stay for a whole and, its wave of positivity is
rapidly taking over the world. I believe that the more a wide variety of healthcare facilities
implement HTM strategies, the better the chances of patients recovering quicker than expected.
For older adults above 50 years living in ALFs, HTM might not bring forth the desired results,
but still, these elderly population stands a chance to lose a lot if they are not reminded always to
take prescribed medications.
As a competent healthcare practitioner, I think that even though HTM does not entirely
solve the problem of failure to complete prescribed medication, there is still no disputing the fact
that it significantly reduces the health implications associated with avoiding medication dosages.
My contribution would be individual, reminding all of my patient to their daily drugs. When I am
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on my shift, I will take it upon myself to make a fixed point of telling all patients to complete
their respective medications, with or without supervision.
Finally, my opinion as a change agent would be leading as an example. Following the
fact on file that change is one of the most inevitable aspects in all human interactions, some
stakeholders might not be in a position to adjust to accommodate the new changes. For this
reason, it is essential to lead by example by enlightening all stakeholders about the merits of
embracing HTM in all healthcare organizations. In other words, HTM is the closest that the
delivery of quality healthcare services has gotten in ages, as far as reminding patients to take
medications goes.
Summary
The results of the surveys conducted in this project indicated that more than 50% of HTN
patients still go on to forget medications or stop taking soon after recovery, despite living under
HTM environments. Further analysis from World Health Organization (WHO) indicates that by
2020, close to 60% of HTN patients will stop adhering to their medications, which will, in turn,
heighten the morbidity and mortality rate of the disease (Lam & France, 2015). Continued
interaction with patients, families, and healthcare providers to explore reasons for medication
nonadherence should be explored.
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Appendix A: Medication Adherence Questionnaire
SURVEY NUMBER___________
Directions: Please complete only one survey for all patients with a diagnosis of hypertension.

This patient is participating in a home assisted telemanagement

1. Do you ever forget to take your medicine?
Yes______No______
2. Are you careless at times about taking your medication?
Yes______No______
3. When you feel better, do you sometimes stop taking your medication?
Yes______No______
4.

Sometimes, if you feel worse when you take the medicine, do you stop taking it?
Yes______No______
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Appendix B: Permission to Use Survey

On Wed, Dec 26, 2018, 2:40 PM Kingsley Ngameduru
<kingsley.ngameduru@waldenu.edu wrote:
Dear Dr. Morisky:
My name is Kingsley Ngameduru. I am a nurse practitioner enrolled in a Doctor of Nursing
Practice program at Walden University. I am currently completing my DNP project titled
Evaluation of Medication Adherence Through the Use of Home-Assisted Telemanagement. The
purpose of this project is to evaluate the improvement in medication adherence in
hypertensive patients through the use of home assisted telemanagement. The practice
question is: Will the use of HAT improve medication adherence in clinic patients diagnosed with
HTN? I am seeking permission to use the 4 point Morisky Scale to assess patients who are
enrolled in the telemanagement program and those that are not.-If you need further
information please contact me at kingsley.ngameduru@waldenu.edu or my committee chair
Dr. Diane Whitehead @ diane.whitehead@mail.waldenu.edu

Thank you for your consideration.
Kingsley Ngameduru, ARNP
From: DONALD MORISKY <dmorisky@ucla.edu>
Sent: Saturday, December 29, 2018 3:17:54 PM
To: Kingsley Ngameduru
Cc: Diane K. Whitehead; ngamedu4@aol.com; healthequity@ph.ucla.edu
Subject: Re: Permission 4 Point Morisky Scale
This email came from an external source.
Thank you very much, Kingsley, regarding your interest in obtaining a license to use the
MMAS-8 diagnostic adherence instrument. Sorry for my delay in responding.
Individual licenses are no longer being provided; you must have your organization or
university purchase the license on your behalf. The cost of the lifetime license is 4000 Euros
plus travel expenses and lodging for a required hands-on training session lasting one day
for three staff personnel. If you cannot convince your university to purchase the license for
use of the copyrighted MMAS-8, you are not permitted to use the MMAS-8.
All users of the MMAS-8 must purchase an institutional license and receive face to face
training in the correct use of my diagnostic adherence assessment instrument. No
individual licenses will be permitted.
Since the cost of the widget is probably more than you can afford, I suggest that you
use the Morisky, Green, and Levine (MGL) Adherence Scale which is in the public
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domain and does not require a license fee. The MGL is NOT the same as the MMAS-4,
which is a copyrighted and trademarked diagnostic adherence assessment instrument
and requires a license to use, just like the MMAS-8 and these tools are NOT in the
public domain. With the MGL, you can make your own translation as this scale is not
copyrighted or trademarked,
Please let me know if you are interested in using the MGL and I will send you the original
publication with the 4-item scale. Thank you again for your interest in using my validated
diagnostic adherence tool.
Please send me a note that you received this email.
Sincerely,
Dmorisky
Donald E. Morisky, Sc.D., M.S.P.H., Sc.M.
Research Professor and Former Chair
Lifetime Career Award, American Public Health Association
Department of Community Health Sciences
UCLA Fielding School of Public Health

Kingsley Ngameduru <kingsley.ngameduru@waldenu.edu>
|
Today, 6:13 AM

Dear Dr. Morisky,
Thanks, for your email in response to my request for permission to use MMAS-8 scale. I would
like to request your MGL adherence scale instead. I appreciate all your help and support.
Thanks,
Kingsley Ngameduru

